Advertisement

Topics

iCAD Announces FDA Clearance of ProFound AI for Digital Breast Tomosynthesis

11:23 EST 7 Dec 2018 | Investing News Network

iCAD (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced clearance by the United States Food and Drug Administration (FDA) for their latest, deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI™, clearing the technology for commercial sales and clinical use in the United States. As quoted in … Continued

The post iCAD Announces FDA Clearance of ProFound AI for Digital Breast Tomosynthesis appeared first on Investing News Network.

Original Article: iCAD Announces FDA Clearance of ProFound AI for Digital Breast Tomosynthesis

NEXT ARTICLE

More From BioPortfolio on "iCAD Announces FDA Clearance of ProFound AI for Digital Breast Tomosynthesis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...